Humabiologics entered into a non-exclusive agreement with Funakoshi to respond to the growing demand of human-derived biomaterials and bioinks serving a broader life sciences customer base of industry partners and academic institutions in the Japanese market.
Humabiologics develops and commercializes high-quality and affordable human-derived biomaterials for translational regenerative medicine applications such as cell therapy, bioprinting, tissue & disease modeling, or drug screening. Funakoshi Co., Ltd, is a leader in manufacturing and distributing life sciences research supplies for 50 years in Japan.
“We are delighted to partner with Funakoshi to make our human products more accessible to researchers in Japan. Funakoshi is a strategic partner with long history and reputation of manufacturing and distributing of life sciences reagents and equipment for life sciences research”, said Dr. Mohammad Albanna, CEO & Founder of Humabiologics. “We look forward to a long-lasting relationship with Funakoshi and to serve their customers with our products to accelerate the development of life-saving human therapies”.
Funakoshi has been offering several useful tools with leading-edge technologies for Japanese researchers from all over the world to support and develop their research. Humabiologics introduced the world’s first native human collagen bioinks and gelatin bioinks. These bioinks are affordable and more clinically relevant, enabling researchers to advance the translational research of bioprinted human organs and tissues.
The company was founded by current CEO Mohammad Albanna, leveraging extensive experience in the field of Tissue Engineering and Regenerative Medicine (as Adjunct Professor of General Surgery at the Wake Forest University School of Medicine). Leveraging proprietary processes to manufacture its products, Humabiologics only partners with FDA-registered and accredited tissue banks around the US to utilize thoroughly screened donated human tissue that will not be used for transplant. Humabiologics product offering includes native human collagen, bone gelatin, and extracellular matrix. These human-derived products are designed to address several ongoing challenges.